It is widely accepted that development of autoimmunity in the central nervous system (CNS) is triggered by autoreactive T cells, that are activated in the periphery and gain the capacity to migrate through endothelial cells at the blood-brain barrier (BBB) into the CNS. Upon local reactivation, an inflammatory cascade is initiated, that subsequently leads to a recruitment of additional immune cells ultimately causing demyelination and axonal damage. Even though the interaction of immune cells with the BBB has been in the focus of research for many years, the exact mechanisms of how immune cells enter and exit the CNS remains poorly understood. In this line, the factors deciding immune cell entry routes, lesion formation, cellular composition as well as distribution within the CNS have also not been elucidated. The following factors have been proposed to represent key determinants for lesion evaluation and distribution: (i) presence and density of (auto) antigens in the CNS, (ii) local immune milieu at sites of lesion development and resolution, (iii) trafficking routes and specific trafficking requirements, especially at the BBB and (iv) characteristics and phenotypes of CNS infiltrating cells and cell subsets (e.g. features of T helper subtypes or CD8 cells). The heterogeneity of lesion development within inflammatory demyelinating diseases remains poorly understood until today, but here especially orphan inflammatory CNS disorders such as neuromyelitis optica spectrum disorder (NMOSD), Rasmussen encephalitis or SUSAC syndrome might give important insights in critical determinants of lesion topography. Finally, investigating the interaction of T cells with the BBB using in vitro approaches or tracking of T cells in vivo in animals or even human patients, as well as the discovery of lymphatic vasculature in the CNS are teaching us new aspects during the development of CNS autoimmunity. In this review, we discuss recent findings which help to unravel mechanisms underlying lesion topography and might lead to new diagnostic or therapeutic approaches in neuroinflammatory disorders including multiple sclerosis (MS).
Neuroinflammatory lesions, especially inflammatory demyelinating lesions as seen in multiple sclerosis (MS), are considered to result from a targeted attack of antigendirected adaptive immune cells against CNS structures. A crucial step in the pathogenesis of autoimmunity is the transmigration of pathogenic T cells across the barriers between the CNS and circulation. Here, the pathogenic T cells can attack the white matter as, for example, in acute disseminated encephalomyelitis (ADEM), the grey matter as in Rasmussen encephalitis (RE) or both, white and grey matter can be affected as it is the case in MS. It is already quite clear that lesion distribution depends largely on disease pathogenesis.
Some rare neurological disorders exhibit very distinct lesion topography such as neuromyelitis optica (NMO), with lesions occurring only in the optic nerve and spinal cord; in RE, only one cerebral hemisphere is affected and lastly in SUSAC syndrome, predominantly the endothelial cells are targeted. In all three examples, the disease is presumably antigen driven, although this has only been demonstrated for NMO so far.
Since various autoimmune disorders of the CNS will be discussed in this review, we introduce very briefly every disease in the following section. The most relevant CNS autoimmune disorder in adults represents MS, a chronic inflammatory demyelinating disease of the CNS affecting more than 2.5 million people worldwide. The hallmarks of MS include destruction of myelin and irreversible axonal injury and loss, which subsequently leads to chronic disability in MS patients. In recent past, Neuromyelitis optica (NMO) was thought to be a clinical variant of MS. However, clinical features, as well as immunological and histopathological features have been identified, which distinguish NMO from MS (Pandit et al. 2015) . Common for NMO are lesions at the spinal cord and/or the optic nerve, as well as the presence of (Wingerchuk et al. 1999 ) and the expressed of autoantibodies against aquaporin 4 (AQP4), an abundant water channel expressed on astrocytes (Lennon et al. 2005; Wingerchuk et al. 2006) . NMO spectrum disorders (NMOSD) include forms of NMO that do not fulfil the NMO criteria from 2006 (Wingerchuk et al. 2006) . Thus, NMOSD also include, for example, recurrent optic neuritis and isolated or recurrent transverse myelitis. So, the spectrum of clinical manifestations in NMO has broadened in the last years. A minority of NMO patients are seronegative for AQP4 autoantibodies and might represent a heterogeneous spectrum of NMO or disease mimics (including MS and other diseases such as paraneoplastic disorders). Acute disseminated encephalomyelitis (ADEM) is characterized clinically by new-onset polyfocal neurologic symptoms including encephalopathy accompanied by multifocal demyelination (Pohl et al. 2016) . ADEM is considered a monophasic disease with highest incidence in early childhood. It is still under debate how often ADEM can present as the first manifestation of MS. Interestingly, Myelin Oligodendrocyte Glycoprotein (MOG) autoantibodies are mainly found in paediatric cases with ADEM but are nearly absent in adult patients with MS or other demyelinating disease. However, recent studies indicated that MOG antibodies are also present in some patients with AQP4-negative NMOSD (Mader et al. 2011; Kitley et al. 2012) and in very few patients with demyelinating syndromes associated with anti-NMDA receptor (Titulaer et al. 2014) . The field of autoimmune encephalitis has expanded over the last few years.
These disorders are of importance, because they can affect children and young adults, are severe, can occur with tumour association and may show relapse after successful treatment. The classic limbic encephalitis, which is frequently associated with hallucinations, seizures or sleep disturbance, is characterized by onconeural antibodies targeting intracellular antigens, which is mostly triggered by lung cancer or testicular tumours (paraneoplastic disorders) (Ramanathan et al. 2014) . Another group of patients with autoimmune encephalitis exhibits antibodies targeting neuronal cell surface molecules. Identified targets include receptors and proteins that have critical roles in synaptic transmissions, such as the N-methyl-D-aspartate receptor, the a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, the caminobutyric acid receptor (GABA B R) and the glycine receptor (Hughes et al. 2010; Lancaster et al. 2010 Lancaster et al. , 2011 . At least for some immune responses, there is evidence that the antibodies alter the structure and function of the antigen, hence showing a pathogenic effect. Rasmussen encephalitis (RE) is a chronic focal encephalitis occurring in children under the age of 15, where only one cerebral hemisphere is affected, resulting in progressive neurological deficits and seizures (Varadkar et al. 2014) . SUSAC syndrome is a rare presumably autoimmune-mediated disease, where the endothelial cells of the small arterial vessels of the brain, the retina and the inner ear are affected, which manifests in focal neurological deficits, headache, hearing loss and branch retinal artery occlusions (Kleffner et al. 2016) .
During the last years, various trafficking routes of autoreactive T cells have been characterized in different animal models of MS and via histopathological staining of MS brain tissue. All in all, there are three already described entry routes. First of all, the early invasion of Th17 cells through the choroid plexus (Reboldi et al. 2009 ), the migration of T cells through the leptomeninges (Howell et al. 2011) as well as the migration through perivascular cuffs at the postcapillary venules (Engelhardt 2008) . Currently, it is not quite clear, what different mechanisms trigger which entry route, however one explanation could be the difference in the epithelial cells of the choroid plexus, which form the blood-cerebrospinal fluid barrier in contrast to the endothelial cells forming the BBB.
Obviously, the different characteristics of the barriers controlling the internal environment of the brain are influencing trafficking of T cells. The blood-brain barrier (BBB), a highly selective diffusion barrier, that separates the blood from the CNS is formed by tight junctions interconnected endothelial cells. The BBB endothelial cells are underlined by a basal lamina and are associated with pericytes and astrocytes. As already mentioned, the blood-cerebrospinal fluid barrier at the choroid plexus consists of epithelial cells. The epithelium secretes the cerebrospinal fluid (CSF), which circulates through the ventricles and around the outside of the brain and spinal cord. The blood-leptomeningeal barrier forms a blood-CSF barrier and consists of endothelial cells of the leptomeningeal microvessels at the surface of the brain and spinal cord.
Furthermore, it has been suggested that not all endothelial cells (EC) in the CNS are functionally the same (Engelhardt 2008; Daneman and Engelhardt 2017) ; for example, capillary endothelial cells differ from endothelial cells at postcapillary venules. There is also emerging evidence that there are regional differences in the characteristics of the BBB, for example, between the CNS grey or white matter or the brain and spinal cord. Obviously, the properties of the BBB and thus also the properties of CNS endothelial cells, can be dynamically altered by different factors such as disease and/ or neuronal or glial cells (Daneman and Engelhardt 2017) . Nevertheless, only a few studies so far have addressed this issue (Macdonald et al. 2010; Nyul-Toth et al. 2016 ) and a lot of open questions remain.
In this review, we will mainly provide an update on current concepts of lesion topography and heterogeneity with a focus on the interaction of T cells with endothelial cells at the BBB. We review what cellular and molecular mechanisms are already known, which trigger lesion development and influence lesion distribution. Several factors are being discussed determining lesion development and lesion distribution in CNS autoimmunity. First of all, the density of antigen expression and its variance in different CNS regions paired with antigen specificity of CNS autoreactive T cells, second the ratio between different T-cell subsets in determining the entry route and lastly the activation status of encephalitogenic T cells and their interaction with the BBB. In the following paragraphs, we will discuss in detail each point and summarize the most recent findings, paying particular attention to the newest technical advances in the field.
Antigen density and antigen specificity of CNS autoreactive T and B cells
The most commonly used animal model to study immunology and brain inflammation in vivo is experimental autoimmune encephalomyelitis (EAE), which can be induced by immunization with different myelin antigens (Gold et al. 2006; Lassmann and Bradl 2017) (Table 1) . Various EAE models have been developed in order to find a good equivalent for MS; however, because of the complexity of the human disease each animal model has its limitations (Table 2) . Nevertheless, each of the available EAE models show variable disease progression and hence lesion development depending on antigen, strain and species used (Mendel et al. 1995; Storch et al. 1998; Kuerten et al. 2006; Hofstetter et al. 2007; Levy et al. 2010) . Primed T cells from the periphery infiltrate and inspect tissues for foreign antigens that are being displayed on resident antigenpresenting cells. CD4+ T cells recognize antigens associated with MHC class II molecules, whereas CD8+ T cell bind to MHC class I complexes (Becher et al. 2006) . The migration behaviour of CNS-specific T cells is determined by the expression pattern and density of its target antigen. While myelin proteins are mainly found in the white matter, as components of the axonal myelin sheath, neuronal antigens are expressed in the grey matter. Hence, antigen specificity of CNS-specific T cells is one major factor influencing lesion distribution. Myelin oligodendrocyte glycoprotein (MOG) and myelin-associated glycoprotein-specific T cells induce lesions in the periventricular and cerebellar white matter, whereas myelin basic protein-specific T cells induce lesions predominantly in the spinal cord of rats (Berger et al. 1997) . S100 beta and glial fibrillary acidic protein-specific T cells (both proteins primarily expressed by astrocytes) induce severe inflammation in the grey matter (Berger et al. 1997) .
In a spontaneous EAE model, where T and B cells are designed to target the myelin antigen MOG, lesions only occur in the optic nerve and spinal cord. For that reason, the model is also known as opticospinal EAE (OSE) (Krishnamoorthy et al. 2006 ). Interestingly, not only oligodendrocytes were targeted in this model (Krishnamoorthy et al. 2009 ), but also neuronal antigens, which demonstrates that even though the antigen is known, the prediction of its target is not always straight forward.
Paraneoplastic neurological disorders are suggested to be associated with autoantibodies against intracellular proteins. Paraneoplastic neurological disorders are triggered by an efficient immune response against a neural self-antigen that is ectopically expressed in neoplastic tumours. Hence, not only tumour cells are attacked, but also neural cells, resulting in neurological damage. Using an artificial antigen, this disease can be modelled in mice Gebauer et al. 2017) . A tumour cell line expressing hemagglutinin (HA), which is found on the surface of influenza viruses, is used to induce an anti-tumour response in mice, that express HA in CNS neurons (CamK-HA mice). Here, it could be shown, that both T-cell subsets, HA-specific CD8+ and CD4+ T cells are needed to control tumour growth and induce CNS inflammation in CamK-HA mice (Gebauer et al. 2017) . Using a similar approach, but expressing HA in hypothalamic orexin (+) neurons (Orex-HA mice) CD8+ T cells were mainly responsible for the loss of orexin(+) neurons and clinical manifestations of narcolepsy (Bernard-Valnet et al. 2016) .
Of course CNS antigen specificity is also relevant in the human situation (Fukazawa et al. 2000) . With regard to MS, a lot of effort was taken during the last decades to unravel disease-specific pathogenic antigens. Based on results from several animal models it seemed most reasonable that myelin antigens were the top candidates in MS. And indeed, in paediatric MS pathogenic antibodies to MOG in the periphery are a common feature, although this only holds true for a small subgroup of adult MS patients. Some studies point to a neuronal antigen, such as neurofascin or contactin (Mathey et al. 2007; Derfuss et al. 2009 ), but when tested in a larger scale of patients, more or less all of the candidates failed. A recent study employing antibody sequencing in MS demonstrates clonally expanding B cells in both compartments, the CNS and the draining cervical lymph nodes (Stern et al. 2014) , reinforcing the hypothesis that MS is an antigendriven disease. Recently developed deep sequencing technology makes it now possible to investigate the B-cell receptor repertoire and also the T-cell receptor repertoire, in order to find hints for antigen-specific B or T-cell responses in MS (Lossius et al. 2016) .
First approaches to study the T-cell responses in MS patients were using spectratyping; a technique investigating the length distribution of the CDR3 (complementary determining region) of the T-cell receptors. So all in all, a Gaussian distribution of a length profile reflects the non-pathogenic situation and every skewed profile points towards an expansion of T-cell clones. So indeed, studies in MS patients using this technique revealed disease-associated T cells in different body compartments (Muraro et al. 2006; Junker et al. 2007 ) and expanded CD8+ T-cell clones (Skulina et al. 2004; Somma et al. 2007) , which can be shared between the periphery and CNS (Salou et al. 2015) . Hence, these studies already supported the hypothesis of MS being an antigen-driven disease. However, in recent years advances in the field of high-throughput sequencing have made it possible to sequence and analyse the CDR3 region of TCRs in a reliable and much more detailed manner. Immunosequencing overcomes the limitations of spectratyping by directly measuring the frequency of individual TCRs, therefore the diversity of the repertoire is not an estimate anymore. The immune receptor nucleotide sequence is a nearly unique molecule tag for a clone, allowing clone tracking over time and between tissues or cell subsets (Robins 2013) .
Even though it is not yet possible to identity the antigenic targets of these T-cell clones in detail, one clear benefit of this technique lies in the possibility to evaluate quite clearly whether a disease is putatively antigen driven or not. Using immunosequencing, our group investigated the Rasmussen encephalitis (RE), a putative paradigm for a MHC class I restricted, CD8-mediated CNS inflammation with attack of neural structures associated with intractable epilepsy. We could demonstrate a strong correlation with the disturbance of the T-cell receptor repertoire with brain atrophy (Schneider-Hohendorf et al. 2016) . Furthermore, this study demonstrated clonal CD8+ T-cell expansion as a pathological feature, which is specific for RE. Via clonal tracking RE-specific T-cell clones or public clones could be identified, that is, T-cell clones exhibiting identical TCR amino acid sequences shared between different individuals, which indicates a common response to the same antigen. Hence, using the novel tool of T-cell receptor deep immunosequencing this study could strengthen the hypothesis that RE is indeed an antigen-driven disease. The next step would be the identification of disease-relevant T-cell antigens. A novel antigen search technology using plasmidencoded combinatorial peptide libraries and a single-cell detection system provides a promising new tool for the unbiased identification of target antigens of CD8 + T cells (Siewert et al. 2012; Ruhl et al. 2016) . This method is able to monitor engineered antigen-presenting cells (APCs) and T cells with a highly sensitive single-cell detection system. COS-7 cells, used as APCs, were co-transfected with a plasmid-coded peptide library and class I MHC cDNA. While the reporter T-cell hybridoma cells were cotransfected with TCR, CD8 and super green fluorescent protein. So only, when the TCR transfectants came in contact with the correct antigen presented by the APC, the cell turned green and could be isolated, subcloned and sequenced. This strategy could be used to characterize antigens of pathogenic T cells, which can be directly isolated from tissue (Siewert et al. 2012) .
Another autoimmune disease of the CNS where the antigen is already known is Neuromyelitis optica spectrum disorder (NMOSD), which shares many features with MS. However, as already mentioned, this disease is characterized by a pathogenic autoantibody response against aquaporin-4 (AQP4) (Lennon et al. 2005) , a water channel expressed on astrocytes, combined with an increased CD4+ T-cell response to aquaporin-4 (Matsuya et al. 2011) . In NMO specific CD4 + T cells might not only provide T cell help for antibody production, but might be also involved in lesion location (Zeka et al. 2015) . Localization of these T cells was shown to be dependent on particular AQP4 peptide specificities. In a Lewis rat model, encephalitogenic T cells specific for the AQP4 epitope (AQP4 268-285 ) were found in the optic nerves, brain and spinal cord, whereas T cells recognizing a different AQP4 peptide remained in the meninges. It is currently under discussion, if lesions in NMO can only develop in the presence of AQP4 autoantibodies (Zeka et al. 2015; Vogel et al. 2017) ; however, a recent study illustrated that pathogenic T cells alone are sufficient to induce a NMO-like disease in mice (Jones et al. 2015) . Considering the fact that about 30% of patients with clinical features of NMO are negative for anti-AQP4 antibodies, both assumptions must be true. Recently, it was found that some aquaporin-4 antibody-negative NMO patients have antibodies against MOG (Reindl et al. 2013; Reindl and Rostasy 2015) . These patients do have a distinct clinical phenotype from AQP4 antibody-seropositive NMO that is characterized by fewer relapses and a better clinical outcome (Zamvil and Slavin 2015) . AQP4 antibodyassociated NMO represents an astrocytopathy, whereas MOG antibody-associated inflammatory demyelinating diseases are predominantly characterized by an oligodendropathy. Therefore, it has been suggested that MOG antibody-positive disease with a NMO-like presentation should be classified as a variant of opticospinal MS (Zamvil and Slavin 2015) . MOG antibodies are mainly found in paediatric cases with ADEM and rarely in adults with bilateral recurrent optic neuritis, MOG antibody-associated encephalomyelitis and anti-NMDA receptor encephalitis. Sometimes even ADEM and NMO overlap with anti-NMDA receptor encephalitis (Titulaer et al. 2014) . Therefore, these clinical presentations are nowadays termed MOG antibody-associated diseases (or MOG spectrum disorders) and are in the spotlight of current research (Spadaro et al. 2015 Spadaro and Meinl 2016) . It is still unclear whether MOG antibodies are truly pathogenic or only a bystander effect or a secondary immune reaction due to an earlier demyelination event (Peschl et al. 2017) . Therefore, the role of MOG antibodies during disease pathophysiology remains an enigma at the moment. However, these antibodies are highly specific and could serve as a biomarker for affected patients.
T-cell subsets are influencing the entry route into the CNS
The second main point influencing lesion distribution is the T cell itself, meaning subset and effector function of the T cell (Fig. 1) . Animal studies have demonstrated interesting differences in the type of lesion development and location between different T-cell subsets. Th1 and Th17 T cells obviously can both induce CNS autoimmunity, however, the pathogenic potential can differ (Domingues et al. 2010) . Furthermore, it could be shown that the ratio of Th17 versus Th1 T cells is crucial for the site of lesion (Stromnes et al. 2008) . Regardless of the ratio, myelin-specific T cells infiltrate the meninges, but only if the proportion of Th17 T cells outnumber Th1 T cells; infiltration and inflammation of the brain parenchyma occurs which goes along with more IL-17A present in the brain. Vice versa, more Th1 T cells provoke spinal cord parenchymal inflammation (Stromnes et al. 2008) .
A recent human study from our group investigated the lymphocyte population in the peripheral blood from RRMS (relapsing remitting MS) patients with primarily cerebral or Depending on the subset of T cell different trafficking routes into the CNS are favoured. Th17 cells preferentially invade the CNS via the choroid plexus using the CCR6-CCL20 axis, but can also invade the CNS via the meninges or postcapillary venules using different adhesion molecules, whereas Th1 cells preferentially invade the spinal cord using a4 integrins. Also, Th17 cells are able to produce IL17A and Granzyme B which can further damage the blood-brain barrier. Another major factor influencing lesion distribution is the antigen expression within the CNS in concert with the antigen-specific T cells targeting grey or white matter. In addition, autoantibodies recognizing different targets in the CNS may contribute to lesion development. Finally, the activation status itself can determine lesion distribution, whereby, for example, B7H1 expression restricts the T-cell infiltration into the brain. MOG (myelin oligodendrocyte protein), AQP4 (Aquaporin 4), NMDA-R (N-methyl-D-aspartate receptor), MMP2 (matrix metalloproteinase-2), MMP9 (matrix metalloproteinase-9).
dominantly spinal cord lesions (Gross et al. 2017) . Here, it could be shown that distinct T helper cells are indeed associated with lesions distribution. In this study, diverging from animal studies, Th17 T cells were associated with spinal cord lesions and Th1 T cells with cerebrum and cerebellar lesions. However, it is possible that the peripheral blood might not reflect the whole picture. T cells might have already migrated into the CNS compartment and could be found in the cerebrospinal fluid (CSF), meaning that the Th17:Th1 ratio in the CSF might differ from the periphery. Therefore, more studies are necessary to draw any final conclusions.
Nevertheless, differential regulation of adhesion molecules, cytokines and chemokines in both T-cell subsets is critical in controlling the entry route. That way, Th1 T cells, in the EAE model, preferentially infiltrate the spinal cord via an a4 integrin-dependent manner; in contrast Th17 T cells enter the brain parenchyma independent of a4 integrin but are dependent on the expression of LFA-1 (aLb2) integrin (Rothhammer et al. 2011) . In order to enter the CNS via the choroid plexus, Th17 T cells need the CCR6-CCL20 axis (Reboldi et al. 2009 ). There is very high and uniform expression of CCL20 in the epithelial cells of the choroid plexus, whereas it is absent in the brain parenchyma. So, for the initial entry of CCR6 expressing cells into the uninflamed CNS through the choroid plexus, the presence of CCL20 seems to be crucial (Reboldi et al. 2009 ).
In humans, Th17 cell are able to use the alternative adhesion molecules MCAM and P-selectin independent of VLA-4 for migration through the BBB (Schneider-Hohendorf et al. 2014). This becomes important, since VLA-4 blockage with natalizumab is a common treatment for RRMS. Also, IL-17A, the main cytokine produced by Th17 cells itself is able to induce BBB breakdown by disrupting tight junctions (Kebir et al. 2007) . It was found that IL-17A increases reactive oxygen species in the brain endothelial cells, resulting in disorganization and loss of tight junction proteins, which subsequently leads to a breakdown of the BBB (Huppert et al. 2010) . In addition, Th17 T cells can also produce the cytolytic enzyme granzyme B, which enables them to kill neurons (Kebir et al. 2007 ). According to this, Th17 are not only able to transmigrate across the BBB, but also actively disrupt the BBB, promote neuronal cell death and lead to a second wave of CD4 + lymphocyte recruitment into the CNS, which causes further damage. At this points, the trafficking of CD4 + T cells via chemokinechemokine receptor becomes important (Charo and Ranshoff 2006; Takeshita and Ransohoff 2012) , for example, CXCR4 expressed on T cells interacts with CXCL12 on the endothelial side, which then leads to a conformational change in the integrins on the T cell side enhancing arrest at the BBB. Hence, targeting the Th17 T-cell subset in autoimmunity pursuing anti-IL17A strategies seems a promising approach to limit transmigration.
The trafficking cues of encephalitogenic CD8+ T cells, even though also a key player in neuroinflammation, are not very extensively studied. So far it could only be demonstrated that also VLA-4 integrin is essential for the migration into the CNS; however, it is suggested that CD8+ T cells might also use additional and maybe until now unidentified adhesion molecules to gain access into the CNS (Galea et al. 2007; Martin-Blondel et al. 2015) .
Histopathological studies of MS provided evidence for extensive grey matter lesions in the cerebral and cerebellar cortex (Bo et al. 2003; Kutzelnigg et al. 2005 Kutzelnigg et al. , 2007 . Cortical lesions occur during early (Lucchinetti et al. 2011) and late (Howell et al. 2011 ) disease state and are strongly associated with meningeal inflammation. The majority of cortical plaques contains CD3+ T cells and CD8+ T-cell infiltrates (Lucchinetti et al. 2011) . The degree of meningeal inflammation even correlates with the extent of active demyelination and neurodegeneration, thus meningeal inflammation seems to drive cortical pathology (Choi et al. 2012; Fischer et al. 2013) . More research needs to be done to shed light on the relationship between early cortical demyelination, cognitive impairments and disease progression.
Activation status of encephalitogenic T cells restricts the migration behaviour
T cells need to be activated in order to invade the CNS from the perivascular space and evoke CNS inflammation. How activated T cells can directly affect BBB integrity is studied in our group using impedance cell spectroscopy of primary mouse brain microvascular endothelial cells (EC) . This assay allows to study integrity and permeability of an endothelial cell monolayer, by measuring changes in transendothelial electrical resistance (TEER) and cell layer capacitance (Ccl). Interestingly, only stimulated but not na€ ıve T cells are capable of inducing disruption of the EC monolayer as visualized by a drop in TEER and increase in Ccl. While only activated T cells gain effector function by producing cytolytic cytokines, na€ ıve T cells are quiescent. Therefore, activation is essential for disrupting the BBB integrity. Moreover, this assay is able to distinguish between different levels of T-cell activation and provides a versatile tool to investigate the targeted modulation of the T cellendothelial cell interaction. With this technique, we could prove that the expression of the co-inhibitory molecule B7-H1 determines the capacity of T cells to disrupt the BBB integrity . B7-H1 ko T cells did induce a more pronounced BBB dysfunction than their wild-type counterparts. A lack of B7-H1 on T cells results in enhanced proinflammatory cytokine production such as INF-c and in an increased production of cytotoxic molecules such as granzyme A and granzyme B upon T-cell activation. Whereby, INF-c and granzyme B were both shown to have an impact on the integrity of the endothelial cell layer, hence both molecules can cause BBB dysfunction.
In vivo, the lack of B7-H1 in OSE mice, a spontaneous EAE model, was associated with an increased BBB leakage in the supratentorial brain regions, especially in the periventricular region. By assessing Evans Blue leakage, all animals showed comparable levels of Evans Blue leakage in the spinal cord, whereas only B7-H1 ko OSE mice displayed also Evans Blue leakage in the brain. Hence, expression of B7-H1 restricts T-cell infiltration into the brain and thereby strongly influencing altered lesion distribution and CNS autoinflammation . Apparently, the activation status itself can determine lesion distribution, or might also support lesion development in a more or less protected site.
Only encephalitogenic T cells, specific for the myelin protein myelin basic protein were able to migrate from the CSF deep into the CNS parenchyma in contrast to brain nonreactive ovalbumin-specific T cells, which remained in the CSF (Schlager et al. 2016) . Thereby, the lack of T-cell reactivation affects the adhesion behaviour in the leptomeningeal milieu.
Visualizing the movement of immune cells into CNS is technically challenging, however, indispensable to understand the basic principles of cell transport between the BBB and the CNS tissue. A recent study (Schlager et al. 2016) uses two-photon microscopy to monitor the trafficking of T cells between leptomeninges and CSF. T cells move through the extracellular matrix network of the subarachoidal space in a random Brownian walk, where they can interact with macrophages. Such interaction, supported by the adhesion molecules VLA-4 and LFA-1 as well as the recognition of the antigen prevents the T cell from being washed into the CSF. Hence, T cells within the CSF display a low activation profile in contrast to T cell in the CNS parenchyma, however, their gene expression profiles are very similar as well as their pathogenic potential. T-cell reattachment to the leptomeninges is mainly driven by antigen-driven T-cell activation, hence activated T cells entered the CNS tissue more effectively than non-activated T cells. In consequence, activated T cells could invade the CNS parenchyma inducing clinical signs of EAE. Reattachment to the leptomeninges was not only dependent on the activation state of the T cell, but also dependent on the inflammatory state of the CNS, meaning antigen-specific T cells primarily invade inflamed CNS tissue. The molecular and cellular requirements for reattachment are the same as for adhesion. Thus, integrinadhesive forces, which are triggered by T-cell activation and/ or chemokines, regulate trafficking between the CSF and CNS (Schlager et al. 2016) .
Another approach to monitor leucocyte penetration of the BBB makes use of matrix metalloproteinase activity as specific marker (Gerwien et al. 2016) . The BBB consists of various components and not only is the interaction of endothelial cells with immune cells essential for shaping inflammatory responses, but also other components in the perivascular space play a role (Sorokin 2010) . In EAE and MS patients, perivascular leucocyte accumulation is associated with gelatinase B/MMP-9 producing cells and in addition MMP-9 is also required for the initial infiltration of immune cells into the CNS. We then developed a molecular imaging method to monitor MMP-9 activity in MS patients using positron emission tomography; it is now possible to monitor very early stages of MS (Gerwien et al. 2016) . Since MMP-9 activity can be used as a marker for leucocyte infiltration and early lesion formation, this will provide new insights into the first steps of lesion development in the human disease.
Traffic from the CNS to the periphery For a long time, it was believed, that the CNS had no lymphatic vasculature. However, a recent study (Louveau et al. 2015) changed this concept dramatically. Louveau et al. (re)discovered and described in detail functional lymphatic vessels lining the dural sinus that are able to transport immune cells from the CSF to the deep cervical lymph nodes. Also, within these lymphatic vessels different immune cells could be detected, especially T cells and antigen-presenting cells. This study could finally explain the presence of CNS antigens in a functionally antigenpresenting cell population within draining cervical lymph nodes found in EAE and MS (de Vos et al. 2002; Van Zwam et al. 2009) . Via this newly discovered drainage route, it is plausible that CNS antigens can reach the periphery, thereby triggering T-cell activation. This study provides new evidence that the brain cannot be seen as a strict immune privileged site anymore and disturbance of the lymphatic vessels in the brain might be an overlooked contributor to CNS pathogenesis, particularly in the context of neurodegenerative diseases.
Conclusion
Further research will probably lead to a better understanding of CNS autoinflammatory diseases, specifically the aspect that determines lesion development and topography. One might anticipate the discovery of even more subgroups, that can be differentiated from a typical MS (spectrum of (auto) inflammatory CNS syndromes). As demonstrated, technical advances can provide new tools to search for disease-specific antigens and better understand antigen-specific encephalitogenic T-cell responses in different CNS inflammatory diseases of the white as well as grey matter. Also, highly sophisticated in vivo imaging techniques broaden our understanding of the migratory behaviour of T cells, as well as the closer examination of the lymphatic vessels will unravel the mechanisms that induce the development of CNS autoimmunity. A novel aspect in this discussion is the role of the BBB and the neurovascular unit. Several recent studies could demonstrate how critical this barrier is for immune cell penetration, reactivation, barrier permeability and thus lesion development and topography. It remains to be better defined how distinct types of brain endothelial cells and components of the neurovascular junction (e.g. pericytes) actively contribute to those processes.
All in all, this will eventually lead to a better understanding of both disease-specific differences and interindividual differences with regard to lesion development and distribution to potentially allow for more tailored therapeutic interventions, for example, based on antigen specificity or direct targeting of molecular cues involved in the extravasation of highly defined T-cell subsets. Lessons from CD49d (integrin a4 subunit) blockade with Natalizumab are of high importance in this context. This antibody neutralizes VLA-4, thereby limiting the traffic of T cells into the CNS. While most cases of classical MS are responding well to this treatment, NMOSD can even exacerbate under Natalizumab treatment (Schneider-Hohendorf et al. 2014; Schwab et al. 2015) . Orphan diseases such as RE might be controlled by limiting access of T cells into the CNS (Bien et al. 2002; Bittner et al. 2013) . Equally important, a better understanding of those processes helps to identify more selective treatment strategies.
